NCT07254611

Combination of HMA and Venetoclax With Posaconazole in Patients With Acute Myeloid Leukemia: A Study of Plasma Concentrations

Completed Last updated 28 November 2025

What this trial tests

trial in AML (Acute Myelogenous Leukemia in 15 participants. Completed in 15 February 2023.

Timeline

12 April 2022

Primary endpoint
15 February 2023

15 February 2023

Quick facts

Lead sponsor	Fondazione IRCCS Policlinico San Matteo di Pavia
Status	Completed
Study type	OBSERVATIONAL
Enrollment	15
Start date	12 April 2022
Primary completion	15 February 2023
Estimated completion	15 February 2023
Sites	1 location across Italy

Conditions studied

• AML (Acute Myelogenous Leukemia — all drugs for AML (Acute Myelogenous Leukemia →

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Who can join

Eligibility, any sex, with AML (Acute Myelogenous Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute Myeloid Leukemia requires intensive chemotherapy treatment, usually followed by an allogeneic bone marrow transplant to reduce the risk of relapse. However, in elderly patients, intensive treatment is often not a feasible option due to the high toxicity, which limits its use. Recently, a combination of hypomethylating agents (HMAs, 5-azacitidine or decitabine), which have a low toxicity profile, and venetoclax, a potent inhibitor of the anti-apoptotic protein Bcl2, has been approved for patients with Acute Myeloid Leukemia who are not candidates for intensive therapy. This combination has shown a significant survival advantage compared to the use of HMA alone (Di Nardo, NEJM 2020). Even in the difficult setting of relapsed/refractory patients, the combination of venetoclax with an HMA agent has led to high rates of global response and good-quality response (global responses 64%, of which 50% were complete responses or with incomplete hematopoietic recovery), as well as disease-free survival rates of 8.9 months for responsive patients, offering many the option for allogeneic transplantation (Aldoss, Haematologica 2018).

However, the venetoclax-HMA combination is associated with hematological toxicity, characterized by deep and prolonged cytopenias, particularly in non-responsive diseases but also after achieving complete remission. Therefore, the risk of infection during periods of severe neutropenia is high. For this reason, although the need for infection prophylaxis in this therapeutic regimen is not yet well defined, it is common practice to administer antifungal prophylaxis with posaconazole, at least during the first two months of therapy or until neutropenia resolves. Posaconazole has been shown to reduce fungal complications during treatment for active Acute Leukemia stages. An increased incidence of invasive fungal infections has been reported in patients with active disease (refractory or at diagnosis). However, this choice must take into account the pharmacological interactions with venetoclax, as posaconazole is a strong inhibitor of cytochrome P3A4 activity and may reduce venetoclax metabolism, thus increasing its plasma levels. To avoid excessive toxicity from venetoclax, its dosage must be adjusted.

Pharmacokinetic studies have shown that during prophylaxis therapy with posaconazole, treatment with venetoclax at doses of 50 or 100 mg was well tolerated. Therefore, based on the increased plasma levels of venetoclax, it is recommended that its dosage be reduced by at least 75% compared to the full dose (Agarwal, Clin Ther 2017).

The available pharmacokinetic studies evaluating venetoclax plasma levels in combination with posaconazole only consider levels after venetoclax has reached steady state (Agarwal, Clin Ther 2017). However, it is known that co-administration can alter venetoclax concentrations until a stable plasma level of posaconazole is reached. During this period, it is important to monitor venetoclax levels closely in order to adjust the dosage and avoid excessive exposure to the drug, thus reducing the risk of increased toxicity, but without excessively lowering plasma levels, which could compromise the treatment's efficacy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.